A news items in the Jan. 24, 2000, issue of BioWorld Today should have said Vivus Inc. initiated enrollment in a Phase II study of its female sexual dysfunction product, Alista, not that it completed enrollment.

Editor's Note: The correction has been made in BioWorld Online.